THE DEAL, AT A GLANCE
From the announcementOblenio
01What it doesBased on these robust preclinical data, Oblenio is moving rapidly toward clinical trial initiation.From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗02Who is involvedBacked by Pfizer Ventures, Deep Track Capital, GV, founding investor Aditum BioFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03What happenedOblenio raised $62M Series B, announced 2026-06-25From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗04Why it mattersOblenio's $62M Series B funds advancement of LBL-051, a trispecific antibody for chronic autoimmune diseases, from positive nonhuman primate data toward clinical trial…From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
Oblenio · Financing Record
Explore source-linked visual explanations for Oblenio. Unsupported claims are withheld while source review continues.
Record 6751 · Recorded date: 2026-06-25
Explore company records →